FOXO4-DRI is a D-retro-inverso peptide designed to selectively target and clear senescent cells, which accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, potentially triggering selective apoptosis of these aged, dysfunctional cells.
Category: Anti-Aging & Longevity. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical only. Single landmark mouse study (Baar et al., Cell 2017). No human clinical trials.
Disrupts the FOXO4-p53 protein-protein interaction in senescent cells. Normally, FOXO4 sequesters p53 in the nucleus of senescent cells, preventing apoptosis. FOXO4-DRI competes with endogenous FOXO4, freeing p53 to trigger mitochondrial apoptosis specifically in senescent cells while sparing…
Safety considerations: No human safety data exists; Theoretical risk of off-target apoptosis in non-senescent cells; Extremely limited preclinical characterization.
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~4.8 kDa |
|---|---|
| Production method | synthetic |
| US regulatory status | Research compound only. No regulatory status. |
Unknown. The only published study was in mice (Baar et al., Cell 2017). No human trials have been conducted. Self-experimentation carries significant unknown risks.
A peptide where all L-amino acids are replaced with D-amino acids and the sequence is reversed. This creates a peptide with similar side chain topology to the original but with enhanced protease resistance.
FOXO4-DRI is a D-retro-inverso peptide designed to selectively target and clear senescent cells, which accumulate with age and contribute to tissue dysfunction. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, potentially triggering selective apoptosis of these aged, dysfunctional cells.
On the PeptideAtlas A–F scale, FOXO4-DRI is rated D (Preclinical Only). Mostly animal or preclinical evidence
Preclinical only. Single landmark mouse study (Baar et al., Cell 2017). No human clinical trials.
Vendors stocking it: OP Labs, Reta-Peptide, Zztai Peptide, Mei Peptide, Pacific Peptide, ZestyRat Research, VitalCell Peptides, Catalyst Peptides, Bluewell Peptides, Growth Guys, Advanced Peptides Australia, Orbitrex Peptides, Dankang BioHealth, Wuhan Newtop Biotech, Prime Source.